Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fierce Pharma
Summit's global PD-1xVEGF data show new promising OS trend
With a fresh data cut in September, the death risk reduction by the ivonescimab regimen expanded to 22% with an improved nominal p value of 0.0332.
Angus Liu
Sep 7, 2025 3:30am
Daiichi, Merck rev up for accelerated approval filing
Sep 7, 2025 10:45am
Senseonics to retake Eversense commercial control from Ascensia
Sep 5, 2025 2:00pm
Medtronic’s Hugo robot logs success in hernia repair trial
Sep 5, 2025 12:00pm
'Several concerning observations': FDA sheds light on rejections
Sep 5, 2025 10:45am
Braveheart pays $65M to challenge BMS for heart disease market
Sep 5, 2025 9:05am
More News
Merck KGaA lands new R&D chief—Chutes & Ladders
Sep 5, 2025 8:30am
BioNTech's ADC beats Roche’s Kadcyla in breast cancer phase 3
Sep 5, 2025 7:30am
Fierce Biotech Fundraising Tracker: MRM Health, Treeline & more
Sep 4, 2025 4:15pm
Fierce Pharma
RFK Jr. blasts pharma industry, touts mRNA vaccine misinformation
Sep 4, 2025 3:51pm
See more stories